Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Guardant Health Inc GH

Healthcare
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer... see more

Recent & Breaking News (NDAQ:GH)

Guardant Health and Patient Advocacy Groups Join Forces to Raise Awareness of the Importance of Complete Biomarker Testing for Patients with Metastatic Non-Small Cell Lung Cancer

GlobeNewswire May 5, 2020

Guardant Health Presents Data at DDW Virtual Meeting Highlighting its Early Cancer Detection Program

GlobeNewswire May 2, 2020

Guardant Health Announces Webcast of First Quarter Financial Results on May 7, 2020

GlobeNewswire April 30, 2020

Study Shows Guardant360 Test Identifies Predictors of Response to PIK3CA Inhibitors in Women with HR+ Metastatic Breast Cancer

GlobeNewswire April 9, 2020

Guardant Health Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Outlook

GlobeNewswire February 24, 2020

Guardant Health to Participate in Upcoming Investor Conferences

GlobeNewswire February 12, 2020

Guardant Health to Report Fourth Quarter and Full Year 2019 Financial Results on February 24, 2020

GlobeNewswire February 10, 2020

Guardant Health Appoints High-Tech-Veteran Kumud Kalia Chief Information Officer

GlobeNewswire January 21, 2020

Guardant Health Announces Collaboration With Amgen to Develop a Global Liquid Biopsy Companion Diagnostic for AMG 510 KRAS G12C Inhibitor

GlobeNewswire January 13, 2020

Guardant Health and NRG Oncology Initiate Randomized Trial to Investigate Circulating Tumor DNA Guided Adjuvant Therapy in Stage II Colon Cancer

GlobeNewswire January 12, 2020

Guardant Health to Present at the 38th Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 30, 2019

One Of The Most Exciting Media Deals Of The Decade

Livemoney December 24, 2019

Guardant Health Receives Expanded Medicare Coverage for Guardant360 Across the Vast Majority of Solid Tumor Cancers

GlobeNewswire December 19, 2019

Where To Look As The Streaming War Heats Up

Livemoney December 17, 2019

Large-Scale Study Shows Guardant360 Effectively Guides Precision Oncology Treatment in Metastatic Breast Cancer Patients

GlobeNewswire December 13, 2019

Study Shows Only 40 Percent of Patients with Metastatic Colon Cancer Receive Guideline-Recommended Biomarker Testing

GlobeNewswire December 11, 2019

Guardant Health Reports Third Quarter 2019 Financial Results and Raises 2019 Revenue Guidance

GlobeNewswire November 7, 2019

Guardant Health to Report Third Quarter 2019 Financial Results on November 7, 2019

GlobeNewswire November 4, 2019

Guardant Health Initiates ECLIPSE Pivotal Study for its LUNAR-2 Blood Test for Colorectal Cancer Screening

GlobeNewswire October 23, 2019

Data Presented at ESMO Show Metastatic CRC Patients with HER2 Amplification Detected by Guardant360 Experience Clinical Benefit After Targeted Therapy

GlobeNewswire September 28, 2019